Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on Eradication Rate of Triple Therapy Including Low Dose-PPI, Clarithromycin, Amoxicillin According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients

NCT03099876 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT03099876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03099876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on Eradication Rate of Triple Therapy Including Low Dose-PPI, Clarithromycin, Amoxicillin According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2017
Completion date
December 1, 2018
Enrollment
320 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection